North America Asthma Therapeutics Market Size & Outlook
North America asthma therapeutics market, 2018-2030 (US$M)
Related Markets
North America asthma therapeutics market highlights
- The North America asthma therapeutics market generated a revenue of USD 13,262.4 million in 2023.
- The market is expected to grow at a CAGR of 4.3% from 2024 to 2030.
- In terms of segment, anti- inflammatories was the largest revenue generating drug class in 2023.
- Combination therapy is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, U.S. is expected to register the highest CAGR from 2024 to 2030.
North America data book summary
| Market revenue in 2023 | USD 13,262.4 million |
| Market revenue in 2030 | USD 17,863.4 million |
| Growth rate | 4.3% (CAGR from 2023 to 2030) |
| Largest segment | Anti- inflammatories |
| Fastest growing segment | Combination therapy |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Anti- inflammatories, Bronchodilators, Combination therapy |
| Key market players worldwide | Teva Pharmaceutical Industries Ltd, GSK PLC, Merck & Co Inc, Roche Holding AG, AstraZeneca PLC, Boehringer Ingelheim, Sanofi SA, Koninklijke Philips NV, BD, Corvus Pharmaceuticals Inc |
Other key industry trends
- In terms of revenue, North America region accounted for 50.2% of the global asthma therapeutics market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- MEA is the fastest growing regional market and is projected to reach USD 1,558.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Asthma Therapeutics Market Scope
Asthma Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America asthma therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to asthma therapeutics market will help companies and investors design strategic landscapes.
Anti- inflammatories was the largest segment with a revenue share of 61.61% in 2023. Horizon Databook has segmented the North America asthma therapeutics market based on anti- inflammatories, bronchodilators, combination therapy covering the revenue growth of each sub-segment from 2018 to 2030.
North America held the largest share of the global asthma therapeutics market. This is due to the local presence of major key players, well-established infrastructure, and increasing prevalence of asthma patients in the region. Asthma is the most common chronic disease among children and is a major noncommunicable disease that affects adults and children.
Moreover, asthma affects more adult women than adult men in the U.S. According to the CDC’s 2020 report, approximately 25 million people in the U.S. were reported to have asthma. According to the Asthma and Allergy Foundation of America (AAFA), around 5 million children in the U.S. have asthma. Furthermore, the rising air pollution, increasing geriatric population, and growing demand for fast-acting & high efficacy drugs are some of the other factors propelling market growth in North America.
Reasons to subscribe to North America asthma therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America asthma therapeutics market databook
-
Our clientele includes a mix of asthma therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America asthma therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into North America asthma therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America asthma therapeutics market size, by country, 2018-2030 (US$M)
North America Asthma Therapeutics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
